4D Molecular Therapeutics, a late-stage biotech company, announced it will present and hold one-on-one meetings at the BofA Securities Healthcare Conference on May 13 and the RBC Global Healthcare Conference on May 19, 2026. The company is advancing treatments for retinal diseases and cystic fibrosis, with its lead product 4D-150 in Phase 3 trials for wet age-related macular degeneration. These presentations aim to update investors on progress and future milestones. Archived webcasts will be available for one year on the company's investor website.
Following Shell's interim dividend payment for Q1 2026 on June 29, several senior executives, including CEO Wael Sawan and CFO Sinead Gorman, acquired shares through dividend reinvestment plans. These shares were obtained in respect of shares previou...
The global aliphatic hydrocarbon solvents and thinners market is projected to grow from $5.26 billion in 2026 to $6.81 billion by 2032, at a CAGR of 4.4%. Growth is fueled by rising demand in coatings, adhesives, and industrial maintenance, with mine...
The global data center semiconductor market is projected to grow from $86.8 billion in 2024 to $265.8 billion by 2029, driven by rising demand for AI-powered servers. The power stage segment will dominate due to its critical role in efficient power d...
The data center direct-to-chip cooling market is projected to grow from $3.33 billion in 2026 to $17.31 billion by 2032, at a CAGR of 26.5%. This growth is driven by the need for precise thermal management in advanced computing, especially for edge c...
The global environmental DNA (eDNA) market is projected to expand from $1.63 billion in 2026 to $5.61 billion by 2031, growing at a 10.2% CAGR. This growth is driven by advanced, non-invasive testing methods that detect species through genetic materi...
